Table 1:

Association Analyses of Prostate Cancer by bin for BRCA1 and BRCA2 PSVs

BRCA1 – All Prostate Cancer
Grouping	Bin	Nucleotide Range	PC+	PC−	HR	95% CI	p-value

BRCA1 Decile	1	≤c.81	11	339	1.06	0.36–3.13	0.917
	2	c.82-c.302	5	325	REF
	3	c.303 – c.1504	4	331	0.82	0.23–2.92	0.761
	4	c.1505 – c.2475	8	431	1.09	0.34–3.43	0.888
	5	c.2476 – c.3319	3	274	0.33	0.15–2.60	0.526
	6	c.3320 – c.3710	5	308	1.32	0.36–4.89	0.677
	7	c.3711 – c.4065	9	318	1.96	0.65–5.86	0.230
	8	c.4066 – c.5030	1	333	0.16	0.02–1.27	0.084
	9	c.5031 – c.5266	13	425	1.68	0.58–4.84	0.339
	10	c.5267+	2	231	0.49	0.10–2.49	0.389

BRCA1 Functional	1	≤c.181	13	515	0.72	0.34–1.53	0.396
	2	c.182-c.1287	6	433	0.83	0.32–2.20	0.713
	3	c.1288-c.2475	9	478	0.93	0.37–2.36	0.887
	4	c.2476-c.3607	5	487	0.58	0.19–1.75	0.333
	5	c.3608-c.4183	12	462	1.19	0.54–2.64	0.671
	6	c.4184-c.5194	5	485	0.38	0.12–1.25	0.112
	7	c.5195+	11	455	REF

BRCA2 – All Prostate Cancer

Grouping	Bin	Nucleotide Range	PC+	PC−	HR	95% CI	p-value

Decile	1	≤c.755	12	296	1.71	0.66–4.46	0.268
	2	c.756-c.1813	25	277	3.38	1.24–9.19	0.017
	3	c.1814-c.3530	6	293	REF
	4	c.3531-c.4965	13	296	2.00	0.69–5.76	0.202
	5	c.4966-c.5909	13	307	2.14	0.66–7.00	0.207
	6	c.5910-c.6275	30	334	2.83	1.21–6.58	0.016
	7	c.6276-c.7007	12	214	2.69	0.89–8.13	0.079
	8	c.7008-c.7913	10	285	2.12	0.60–7.42	0.240
	9	c.7914-c.8953	26	281	3.32	1.28–8.65	0.014
	10	c.8954+	23	274	4.26	1.60–11.37	0.004

Functional	1	≤c.1000	27	398	1.39	0.74–2.64	0.307
	2	c.1001-c.3005	14	397	0.80	0.39–1.63	0.535
	3	c.3006-c.5172	16	408	REF
	4	c.5173-c.6255	32	498	1.01	0.53–1.93	0.967
	5	c.6256-c.7436	24	400	1.44	0.74–2.82	0.286
	6	c.7437-c.8616	28	390	1.68	0.91–3.13	0.100
	7	c.8617+	29	366	1.64	0.90–3.01	0.106

Elevated vs. No Elevated PCa Risk	1	≤c.755	12	296	0.73	0.40–1.31	0.288
	2^*	c.756-c.1000	15	102	2.83	1.71–4.68	4×10⁻⁵
	3	c.1001-c.7913	94	1904	REF
	PCCR	c.7914+	49	555	1.78	1.25–2.52	0.001

Elevated vs. No Elevated PCa Risk	No Elevated PCa Risk	≤c.755, c.1001-c.7913	106	2,200	REF
Elevated vs. No Elevated PCa Risk	Elevated PCa Risk	c.756-c.1000, c.7914+	65	657	2.02	1.48–2.77	9×10⁻⁶

BRCA2 –Prostate Cancer by Gleason Grade
Gleason 8+	Bin	Nucleotide Range	PC+	PC−	HR	95% CI	p-value

Bins with Elevated Risk	1	≤c.755	2	299	0.53	0.12–2.32	0.399
	2	c.756-c.1000	6	108	4.95	2.12–11.54	2×10⁻⁴
	3	c.1001-c.7913	19	1940	REF
	PCCR	c.7914+	18	572	3.11	1.63–5.95	0.001

Bins with Elevated Risk	No Elevated PCa Risk	≤c.755, c.1001-c.7913	21	2239	REF
Bins with Elevated Risk	Elevated PCa Risk	c.756-c.1000, c.7914+	24	680	3.80	2.10–6.89	1×10⁻⁵

Gleason ≤ 7

Bins with Elevated Risk	1	≤c.755	3	298	0.47	0.14–1.57	0.221
	2^*	c.756-c.1000	6	108	3.29	1.38–7.83	0.007
	3	c.1001-c.7913	36	1923	REF
	PCCR	c.7914+	17	573	1.56	0.88–2.78	0.130

Bins with Elevated Risk	No Elevated PCa Risk	≤c.755, c.1001-c.7913	39	2221	REF
Bins with Elevated Risk	Elevated PCa Risk	c.756-c.1000, c.7914+	23	681	1.89	1.14–3.14	0.014

Bin containing Icelandic Founder PSV c.771_775del